On November 11, 2021 Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, reported that Company management will participate in three upcoming investor conferences and include an update on progress with its OBX-115 program (Press release, Obsidian Therapeutics, NOV 11, 2021, View Source [SID1234595254]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies Global Healthcare Conference (London) |Presenting onTuesday, November 16, 2021 at 9:20 a.m. GMT | View Source
Piper Sandler 33rd Annual Virtual Healthcare Conference |Presentations will be available for registered attendees from Monday, November 22, 2021 at 10:00 a.m. ET through December 2, 2021
RBC Capital Markets Healthcare Private Company Conference | Presenting on Wednesday, December 15, 2021 at 3:50 p.m. ET
About OBX-115

OBX-115 is Obsidian’s lead cytoTIL15 program, currently in preclinical development for the treatment of patients with metastatic melanoma and other solid tumors. OBX-115 is a novel engineered tumor infiltrating lymphocyte therapy armed with regulated membrane-bound IL15 that is designed to remove the need for concomitant IL2 therapy, a toxic and costly requirement for conventional TILs. The Company expects to submit an IND for OBX-115 in mid-2022.